Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score

The Lancet Oncology

Volumn 12, Issue 6, 2011, Pages 568-574

  Yang, Hwai I ^a,b   Yuen, Man Fung ^c   Chan, Henry Lik Yuen ^d   Han, Kwang Hyub ^e   Chen, Pei Jer ^f   Kim, Do Young ^e   Ahn, Sang Hoon ^e   Chen, Chien Jen ^a,f   Wong, Vincent Wai Sun ^d   Seto, Wai Kay ^c  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e Yonsei University College of Medicine   (South Korea)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CALIBRATION; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA DETERMINATION; FEMALE; GENDER; HEPATITIS B; HONG KONG; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SOUTH KOREA; VALIDATION PROCESS;

EID: 84984550778     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70077-8     Document Type: Article

References (24)

1. Lee WM Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
2. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067-1077.
3. Han KH, Ahn SH How to predict HCC development in patients with chronic B viral liver disease?. Intervirology 2005, 48:23-28.
4. Chen CJ, Yu MW, Liaw YF Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997, 12:S294-S308.
5. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168-174.
6. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006, 101:1797-1803.
7. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009, 50:80-88.
8. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
9. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004, 328:983.
10. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54:1610-1614.
11. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004, 53:1494-1498.
12. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008, 26:177-182.
13. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:1134-1143.
14. Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009, 101:1066-1082.
15. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. European Association for the Study of the Liver.
16. Ahn SH, Chan HL, Chen PJ, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010, 4:386-395.
17. Lok AS, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
18. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
19. Bedossa P, Dargere D, Paradis V Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
20. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis b virus infection. J Clin Oncol 2010, 28:2437-2444.
21. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010, 28:1660-1665.
22. RB D'Agostino, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
23. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
24. Mok TS, Yeo W, Yu S, et al. An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol 2005, 23:8041-8047.